يعرض 221 - 240 نتائج من 17,927 نتيجة بحث عن '(( significant gap decrease ) OR ( significant ((a decrease) OR (step decrease)) ))', وقت الاستعلام: 0.55s تنقيح النتائج
  1. 221
  2. 222

    Participant characteristics. حسب Ronald Kusolo (13200268)

    منشور في 2025
    الموضوعات:
  3. 223
  4. 224
  5. 225

    HFD decreases intermediate-term memory. حسب Tong Yue (6033305)

    منشور في 2025
    "…<p>(A) The survival rate of 10d <i>Canton-S</i> fed with ND or HFD was observed for 7 days. …"
  6. 226
  7. 227
  8. 228
  9. 229
  10. 230
  11. 231
  12. 232

    Analysis of the significantly different metabolomic features. حسب Bhuripit Saraphol (20855573)

    منشور في 2025
    "…<b>(B)</b> Volcano plot highlighting the significantly different metabolomic features. The red dots represent the features with significantly increased intensity, and the purple dots represent the features with significantly decreased intensity. …"
  13. 233
  14. 234
  15. 235

    A summary of the included study characteristics. حسب Zahra Tajik (20752452)

    منشور في 2025
    "…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …"
  16. 236
  17. 237
  18. 238

    Predictive Significance of Glycosyltransferase-Related lncRNAs in Endometrial Cancer: A Comprehensive Analysis and Experimental Validation حسب Xiaoyu Shen (4715430)

    منشور في 2025
    "…And the low-risk cohort exhibited increased immune infiltration and decreased tumor purity. Additionally, significant differences in tumor mutation profiles were observed, with the tumor mutation burden (TMB) being higher in the low-risk cohort, suggesting a potentially better response to immunotherapy. …"
  19. 239
  20. 240